US Department of Agriculture (USDA) Agricultural Research Service (ARS)’s Post

Taconic will be joined by BIOQUAL, Inc. Vice President Dr. Swagata Kar to discuss how the hACE2 AC70 mouse can be utilized for efficacy studies related to COVID-19 prevention and treatment. Dr. Kar has served as a principal investigator on more than 200 COVID-19 related projects over the past three years. Register for this free webinar to learn about key considerations for SARS-CoV-2 study design, including biosafety and how endpoint selection impacts group size: https://bit.ly/3v1tQwb

Do you have an idea that could improve #InfectiousDisease care? 💡 Applications for the 2024 IDEA Incubator and the MTEC Diagnostic Technologies for Unknown Pathogen Identification Award are now open! Apply to compete in the “Shark Tank”-style competition The recipient of this award will receive a $10,000 cash award and will present their innovation at the IDea Incubator Innovator of the Year live pitch competition event during IDWeek 2024, Oct. 16-19, in Los Angeles, CA. Exact date TBD. The Innovator of the Year winner will receive an additional $5,000 cash award as well as an accelerator package to assist in the launch or scaling of the innovation. The award recognizes groundbreaking contributions to the field of infectious diseases, specifically focusing on advancements of pathogen-agnostic diagnostics of unknown pathogens. Learn more and apply: https://buff.ly/3KFE2z3 • June 30, 2024: Applications close • July 15, 2024: All applicants are notified of award decisions #PatientCare #Diagnosis #DiagnosticTechnology #UnknownPathogens #Infection #Disease #Detection #PathogenIdentification #ResearchAndDevelopment #Telehealth #Ideas Changing Our World IDSA Foundation

For the conclusion of our #BioIVTvision series of #2024Predictions, Shannon Richey, VP and GM of Disease State, sheds light on transformative changes ahead. Disease state testing, historically invasive, is undergoing a revolution. Biofluid testing on blood is enabling early #diseasedetection and helping build understanding of the uniqueness of each person's disease. Overall, biofluid testing promises to have game-changing impact on providing timely answers to patients about their conditions. “In 2024, I expect to see the transition accelerate from invasive tests to non-invasive tests that are done on blood through biofluid testing. The goal of this is to catch disease earlier and get answers to patients quicker, and if done correctly, there is a huge opportunity to look for cancers at a very early stage, for example.” - Shannon Richey, VP and GM at BioIVT #Biospecimens #Biotech

Less than two weeks to go until the AMR Conference 😀. Here is your session update for the weekend: "Multisectoral response to a multisectoral challenge". AMR is not just about infectious disease. It also poses significant multisectorial challenges, including other areas of public health or climate change, to name a few. The panel discussion moderated by Florence Sejourne, AUROBAC THERAPEUTICS will convene a session with experts from various sectors to help shape the multisectoral response needed to combat AMR. 👉 Dr Cary Adams, Union for International Cancer Control (UICC) will describe the impact of AMR on cancer. 👉 Pratik Bhatnagar, IQVIA will investigate the impact of climate change. 👉 Mark Albrecht, Biomedical Advanced Research and Development Authority (BARDA) will expose the US approach to AMR as a 21st century health security threat 👉 Aanika Dalal, ARMOR - Alliance for Reducing Microbial Resistance will describe her battle to pursue policy change with the energy of Youth engagement. A closing session, but with an open mindset! Don’t miss it! You can still register for the conference here: https://lnkd.in/de_vAkF And stay tuned next week for a final round of session updates 🧐.

Less than two weeks to go until the AMR Conference 😀. Here is your session update for the weekend: "Multisectoral response to a multisectoral challenge". AMR is not just about infectious disease. It also poses significant multisectorial challenges, including other areas of public health or climate change, to name a few. The panel discussion moderated by Florence Sejourne, AUROBAC THERAPEUTICS will convene a session with experts from various sectors to help shape the multisectoral response needed to combat AMR. 👉 Dr Cary Adams, Union for International Cancer Control (UICC) will describe the impact of AMR on cancer. 👉 Pratik Bhatnagar, IQVIA will investigate the impact of climate change. 👉 Mark Albrecht, Biomedical Advanced Research and Development Authority (BARDA) will expose the US approach to AMR as a 21st century health security threat 👉 Aanika Dalal, ARMOR - Alliance for Reducing Microbial Resistance will describe her battle to pursue policy change with the energy of Youth engagement. A closing session, but with an open mindset! Don’t miss it! You can still register for the conference here: https://lnkd.in/de_vAkF And stay tuned next week for a final round of session updates 🧐.

Are you at #ADLM2024? Today and tomorrow exciting abstracts will be presented. Head over to the poster zone for one-on-one conversations about the research, methodology, results, and potential implications. Don't miss out! #A-241: Donna M. Wolk, PhD, from Geisinger will discuss how acute febrile illnesses (AFIs) pose a global healthcare challenge, requiring rapid and accurate diagnostics to optimize treatment. https://lnkd.in/dwxc_uY5 #B-047 Brian DuChateau from MeMed will discuss how distinguishing between viral and bacterial infections is crucial for effective management of suspected infections; the MeMed BV® (MMBV) test, using three biomarkers (TRAIL, IP-10, CRP), has shown over 95% negative predictive value and is evaluated here for its real-world application in a micro-hospital Emergency Department. https://lnkd.in/dxZrKR3x

Exciting news! 🚀🚀 Our new datasets are landing on Health Data Research UK (HDR UK)'s Gateway next week! From Immune Checkpoint Inhibitors to Bronchiectasis, watch this space to find out more about our latest dataset releases! 🔬📊 #DataScience #HealthData #CancerResearch #Bronchiectasis

The 2024 Next Generation Dx Summit is set to take place from August 19-21 at the Capital Hilton in Washington, D.C. This premier event will bring together experts and professionals from across the diagnostics field to discuss the latest advancements and trends in areas such as point-of-care testing, infectious disease diagnostics, liquid biopsy, multi-cancer early detection, and companion diagnostics. Key highlights include plenary sessions focusing on regulatory developments for laboratory-developed tests (LDTs) and the evolving landscape of diagnostic technologies. Attendees can engage in interactive discussions, attend specialized forums, and participate in 1-on-1 networking sessions, making it an excellent platform for collaboration and knowledge sharing. #NextGenDx2024, #DiagnosticsInnovation, #PointOfCareTesting, #LiquidBiopsy, #InfectiousDisease, #CompanionDiagnostics, #DxSummit, #HealthcareInnovation, #MedicalTech, #BiotechEvents, #ImportExport, #GlobalTrade, #IORServices, and #RegulatoryCompliance.

Experience the Apex of Precision Medicine with NGS! 🚀From decoding genes to targeting pathogens, your personalised healthcare journey is shaped by our specialised as well as custom panels. Immerse yourself in the magic of NGS—let's revolutionise healthcare together! 💙 🧬 #NGSRevolution #genomicmedicine #PersonalisedHealthcare #HealthcareTransformation #InnovateWithUs

On this International Day of Friendship, celebrate the people who bring joy and laughter into your life. Encourage your friends to prioritize their health and share the importance of multi-cancer early detection screening: https://bit.ly/3RPR2Gu #InternationalDayOfFriendship #MultiCancerEarlyDetection #MCED #TestForThem See Important Safety Information: http://bit.ly/33m8pFa Galleri should be used in addition to healthcare provider recommended screenings. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.